Evidence map›Paper›PMID 42772935›Full record

ArticleImmunoHorizons2026

Evaluating novel antibodies for cytokine profiling in the guinea pig model.

Lea Maristela, Alyssa Longworth, David F Ackart, Faye Lanni, Joseph Gibb, Ashley Freedman, Olivia R Miller, Ling Cai, Hong Qi, Susan L Baldwin and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ImmunoHorizons, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Lea MaristelaMycobacteria Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO, United States.
Alyssa LongworthMycobacteria Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO, United States.
David F AckartMycobacteria Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO, United States.
Faye LanniMycobacteria Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO, United States.
Joseph GibbMycobacteria Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO, United States.
Ashley FreedmanMycobacteria Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO, United States.
Olivia R MillerMycobacteria Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO, United States.
Ling CaiQooLabs, Inc., Carlsbad, CA, United States.
Hong QiQooLabs, Inc., Carlsbad, CA, United States.
Susan L BaldwinPhoenix Immune Mechanisms of Protection Against TB (IMPAc-TB) Center, Seattle, WA, United States.
Sasha E LarsenPhoenix Immune Mechanisms of Protection Against TB (IMPAc-TB) Center, Seattle, WA, United States.
Carolina MehaffyMycobacteria Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO, United States.
Marcela Henao-TamayoMycobacteria Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO, United States.
Rhea N ColerPhoenix Immune Mechanisms of Protection Against TB (IMPAc-TB) Center, Seattle, WA, United States.
Brendan K PodellMycobacteria Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO, United States.ORCID 0000-0003-2548-8826

Funding

IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB)75N93021C00029 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI COLER, RHEA · 2022 to 2025
$35.2M
National Institute of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services 75N93021C00029NIH HHS 75N93021C00029
6 · The paper itself

Abstract

The guinea pig model of Mycobacterium tuberculosis (Mtb) infection offers distinct advantages compared to conventional mouse models. Namely, the guinea pig model develops circumscribed granulomas with central necrosis which most closely resembles that of human granulomas. However, a limitation of this model is the lack of available reagents to characterize the Mtb immune response. To better leverage this representative model, a set of recombinant rabbit monoclonal antibodies targeting guinea pig cytokines were generated and validated. Using established stimulation conditions for primary guinea pig cells capable of producing specific cytokine profiles, the reactivity and specificity of these antibodies to their biological target were evaluated. These antibodies were then evaluated individually for direct ELISA and immunohistochemistry or part of a pair for sandwich ELISA and ELISpot techniques. Utilized in a low-dose aerosol model of Mtb in the guinea pig, the utility of these antibodies to detect specific immune cytokines generated in response to infection is demonstrated. Collectively, these antibodies will provide a more comprehensive understanding of immune kinetics, vaccine response, and comparative immunology across the guinea pig model of tuberculosis and other infectious diseases.

Indexed as

Antibodies, MonoclonalCytokinesMycobacterium tuberculosisTuberculosisAnimalsDisease Models, AnimalEnzyme-Linked Immunosorbent AssayEnzyme-Linked Immunospot AssayFemaleGuinea PigsImmunohistochemistryRabbitsAntibodies, MonoclonalCytokinesantibodiescytokineguinea pigtuberculosis

Identifiers

PMID42772935
PMCPMC13597125

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.